LGND
Ligand Pharmaceuticals Incorporated
303.00$
+0.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -90.5% | -25.9% | -376.3% | -147.9% | -98.4% | -26.1% | -26.0% | 0.2% | 3.5% | 4.7% | -98.3% | -757.9% | -75.5% | -86.8% | -115.0% | -3.9% | 0.5% | 42.2% | 31.9% | 58.0% | 57.8% | 66.3% | 77.2% | -24.4% | 33.4% | 32.6% | 70.2% | 37.8% | 58.1% | 18.4% | |
| 25.5% | 19.0% | 43.5% | 18.1% | 14.5% | 8.6% | 10.8% | 10.1% | 9.3% | 10.6% | 11.5% | 20.3% | 3.9% | 8.0% | 9.4% | 9.3% | 8.7% | 5.4% | 4.1% | 3.7% | 10.4% | 8.3% | 5.9% | 36.4% | 17.1% | 21.1% | 26.2% | 27.8% | 21.1% | 13.3% | |
| – | – | – | – | – | – | – | – | – | 0.1% | 3.8% | 58.8% | -2.0% | 8.6% | 9.9% | 11.2% | 13.0% | 11.6% | 17.5% | 17.3% | 17.3% | 17.7% | 8.3% | 20.4% | 18.8% | 16.1% | 30.7% | 19.6% | 24.6% | 17.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -32.3% | 13.0% | – | 14.7% | -280.6% | 49.4% | 51.9% | 3.6% | -596.8% | -1.1% | 2.6% | 24.4% | – | – | – | |
| -10.9% | 23.4% | -8.5% | -21.3% | 16.1% | -0.1% | -7.0% | 10.5% | -73.4% | 15.1% | -58.6% | -433.0% | -4.8% | -47.1% | -105.1% | -19.6% | -8.8% | -1.4% | -17.0% | 1.1% | -9.7% | -8.1% | -15.5% | -3.5% | -6.2% | -21.6% | 33.5% | -26.2% | 11.6% | -4.7% | |
| 1.1% | 8.3% | 13.6% | 96.6% | 2.3% | 2.6% | 3.3% | 2.0% | 2.2% | 20.2% | 1.3% | 3.4% | 1.8% | 1.3% | 0.3% | 0.3% | 27.5% | 10.1% | 7.0% | 15.1% | 26.0% | 5.1% | 4.7% | 2.1% | 2.7% | 3.6% | 9.1% | 41.0% | 11.8% | 0.2% | |
| 20.4% | 8.3% | -161.6% | -60.9% | 30.5% | -5.5% | -108.9% | -17.4% | 12.0% | -19.1% | 139.7% | 2,666.6% | -89.4% | 63.6% | 61.8% | -83.7% | 4.0% | -10.2% | -3.1% | -156.9% | -131.4% | -59.7% | -168.3% | 388.2% | 141.6% | 12.6% | 83.4% | -8.9% | -86.0% | -140.7% | |
| – | – | – | – | – | – | – | 0.8% | – | – | – | 1,958.7% | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | 2.5% | 1.8% | 6.3% | 2.5% | – | – | – | |
| – | – | – | – | – | – | – | -11.2% | – | – | – | -307.2% | -5.9% | – | -0.4% | -0.2% | 20.4% | 0.0% | -105.3% | -0.7% | -3.6% | -1.4% | -48.9% | -376.7% | -47.7% | -7.6% | -4.2% | -3.5% | -3.1% | -5.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 99.9% | -8.0% | – | -30.3% | 740.2% | 488.5% | 377.3% | 205.0% | -22.7% | -135.9% | -68.3% | -133.0% | -58.6% | 0.0% | 131.9% | |
| 121.5% | 70.6% | 371.8% | 201.7% | 25.0% | 46.6% | 157.3% | 29.0% | 4.8% | -0.1% | 23.6% | -2,541.5% | -11.0% | -9.5% | -0.7% | 99.9% | 12.5% | -33.6% | 201.5% | 11.6% | 1.4% | -5.3% | 130.7% | -403.4% | -189.9% | -57.0% | -140.6% | -45.7% | 58.1% | 159.7% | |
| 51.4% | 53.0% | -166.7% | -7.1% | -43.0% | 15.1% | 22.4% | 11.8% | 20.4% | -14.5% | 65.0% | -632.8% | -175.9% | -32.7% | -53.9% | 12.3% | 17.0% | -1.5% | 230.2% | -87.3% | -72.2% | 1.3% | 39.4% | -39.5% | -14.9% | -11.8% | 13.0% | -16.8% | 29.5% | 38.3% | |
| -91.6% | -34.2% | -389.8% | -244.5% | -100.7% | -28.7% | -29.3% | -1.8% | 1.3% | -15.4% | -99.5% | -761.3% | -77.3% | -88.1% | -115.3% | -4.2% | -27.0% | 32.2% | 24.9% | 42.9% | 31.8% | 61.2% | 72.4% | -26.5% | 30.6% | 29.0% | 61.1% | -3.3% | 46.3% | 18.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.